Name: High-Throughput Screening of Compounds Using Neutrophils Isolated from Human Blood in a 384-Well Plate Format
Uploaded: 2024-02-02T12:00:00
Description: Watch this Scientific Journal Video about High-Throughput Screening of Compounds Using Neutrophils Isolated from Human Blood in a 384-Well Plate Format at JoVE.com

high-throughput screening of compounds using neutrophils isolated from human blood in a 384-well plate format

Screening von β2-Integrin-Aktivierungsinhibitoren in humanen Neutrophilen

Many inflammatory diseases are characterized by the infiltration of neutrophils at the site of swelling or injury1. To infiltrate these tissues, neutrophils must complete the neutrophil recruitment cascade, which involves arrest to the endothelium, extravasation across the vessel wall, and recruitment into the tissue2. Circulating neutrophils need &#946;2 integrin activation to complete this cascade, especially for the arrest phase. Thus, integrin-inhibiting drugs that reduce neutrophil adhesion, extravasation, and recruitment may effectively treat inflammatory diseases3,4.
&#946;2 integrins have been targeted for inflammatory diseases before. Efalizumab, a monoclonal antibody directly targeting integrin &#945;L&#946;2, was developed to treat psoriasis5. However, efalizumab was withdrawn due to its lethal side effect - progressive multifocal leukoencephalopathy resulting from JC virus reactivation6,7. New anti-inflammatory integrin-based therapies should consider maintaining the anti-infection functions of leukocytes to minimize side effects. The side effects of efalizumab might be due to the prolonged circulation of monoclonal antibodies in the bloodstream, which could inhibit immune functions in the long term8. A recent study shows that efalizumab mediates &#945;L&#946;2 crosslinking and the unwanted internalization of &#945;4 integrins, providing an alternative explanation for the side effects9. Thus, short-lived, small-molecule antagonists might avoid this problem.
A high-throughput method to screen small-molecule &#946;2 integrin antagonists using human neutrophils is presented here. &#946;2 integrin activation requires conformational changes of the integrin ectodomain to gain access to and increase its binding affinity to its ligand. In the canonical switchblade model, the bent-closed integrin ectodomain first extends to an extended-closed conformation and then opens its headpiece to a fully activated extended-open conformation10,11,12,13. There is also an alternative pathway that starts from the bent-closed to bent-open and extended-open, eventually14,15,16,17,18,19. The conformation-specific antibody mAb24 binds to an epitope in the human &#946;2-I-like domain when the headpiece of the ectodomain is open20,21,22,23.
Here, mAb24-APC is used to determine whether the &#946;2 integrins are activated. To activate neutrophils and integrin, N-formylmethionyl-leucyl-phenylalanine (fMLP), a bacterial-derived short chemotactic peptide that can activate neutrophil &#946;2 integrins24, is used as a stimulus in this protocol. When fMLP binds to the Fpr1 on neutrophils, downstream signaling cascades involving G-proteins, phospholipase C&#946;, and phosphoinositide 3-kinase &#947; are activated. These signaling events ultimately result in integrin activation via the inside-out signaling pathway18,25. Besides small molecule antagonists that directly bind to &#946;2 integrins and prevent conformational changes of integrin activation26, compounds that can inhibit components in the &#946;2 integrin inside-out activation signaling pathway would also be detected with this method. Automated flow cytometers enable high-throughput screening. Identifying new antagonists may not only deepen our understanding of integrin physiology but also provide translational insight into integrin-based anti-inflammation therapy.

Autor im Rampenlicht: Entwicklung einer Methode zur Identifizierung kleiner molekularer Antagonisten der β2-Integrin-Aktivierung 

Eine auf Durchflusszytometrie basierende Hochdurchsatztechnik für das Screening von Integrin-hemmenden Medikamenten

Our research is focused on neutrophil integrin, and in this study we aim to establish a method to find small molecular antagonists of Beta-2 integrin activation. We believe with this method we can find new antagonists that may deepen our understanding in integrin physiology, and also provide translational insight into integrin-based anti-inflammatory therapy. In the future, we will focus on discovering new anti-inflammatory drugs and dissecting their mechanisms of action.

Watch this Scientific Journal Video about High-Throughput Screening of Compounds Using Neutrophils Isolated from Human Blood in a 384-Well Plate Format at JoVE.com

High-Throughput Screening of Compounds Using Neutrophils Isolated from Human Blood in a 384-Well Plate Format  

Hochdurchsatz-Screening von Verbindungen mit Neutrophilen, die aus menschlichem Blut isoliert wurden, in einem 384-Well-Plattenformat

Mit einer serologischen Pipette vorsichtig vier Milliliter heparinisiertes menschliches Blut über acht Milliliter Dichtegradientenmedium in ein 15-Milliliter-Zentrifugenröhrchen schichten. Zentrifugieren Sie das Blut bei 550 g für 30 bis 50 Minuten bei 20 Grad Celsius. Entfernen Sie dann mit einer Ein-Milliliter-Pipette die obere Schicht mit Plasma und mononukleären Zellen.Sammeln Sie Neutrophile aus dem unteren trüben Band und etwa drei bis vier Milliliter unterhalb der klaren Flüssigkeit in ein 15-Milliliter-Zentrifugenröhrchen, das 10 Milliliter PBS enthält. Drehen Sie das Röhrchen vorsichtig zwei- bis dreimal um, um die neutrophile Suspension zu mischen. Zentrifugieren Sie die Neutrophilensuspension bei 400 G für 10 Minuten bei 20 Grad Celsius, dann dekantieren Sie vorsichtig den Überstand aus dem Röhrchen und resuspendieren Sie das Pellet in fünf Millilitern PBS.Auch hier zentrifugieren Sie die Suspension bei 300 G für 10 Minuten bei 20 Grad Celsius. Nachdem Sie den Überstand entfernt haben, verwenden Sie eine Vakuumabsaugung, um Restüberstände an der Rohrwand und um die Röhrchenmündung herum zu entfernen. Resuspendieren Sie das Pellet in einem Milliliter neutrophilem Medium.Kombinieren Sie einen Milliliter 1,2 Mikrogramm pro Milliliter Antikörperlösung mit 0,2 Milliliter neutrophilem Medium in einem 1,5-Milliliter-Röhrchen. Geben Sie 25 Mikroliter Antikörperlösung in die Negativkontrollvertiefungen in einer 384-Well-Platte. In einem 15-Milliliter-Röhrchen werden neun Milliliter der Antikörperlösung, 21,6 Mikroliter der FMLP-Lösung und 1,7784 Milliliter neutrophiles Medium vermischt.Geben Sie 25 Mikroliter dieser Mischung in die Positivkontrolle und testen Sie die Vertiefungen in einer 384-Well-Platte. Übertragen Sie mit einer Mehrkanalpipette fünf Mikroliter Verbindungslösung von der Verbindungsbibliotheksplatte auf die 384-Well-Platte. Zentrifugieren Sie die Suspension bei 500 g für eine Minute.Geben Sie 20 Mikroliter Neutrophilensuspension mit einer 16-Kanal-Pipette in jede Vertiefung. Die Platte auf einem Shaker bei 300 U/min 10 Minuten lang inkubieren. Um die Zellen zu fixieren, fügen Sie drei Mikroliter 16%iges Paraformaldehyd in jede Vertiefung hinzu und inkubieren Sie 10 Minuten lang auf Eis.

high-throughput-screening-compounds-using-neutrophils-isolated-from

Research

JoVE Journal

Immunology and Infection

High-Throughput Screening of Compounds Using Neutrophils Isolated from Human Blood in a 384-Well Plate Format

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

This protocol aims to establish a method for identifying small molecular antagonists of &#946;2 integrin activation, utilizing conformational-change-reporting antibodies and high-throughput flow cytometry. The method can also serve as a guide for other antibody-based high-throughput screening methods. &#946;2 integrins are leukocyte-specific adhesion molecules that are crucial in immune responses. Neutrophils rely on integrin activation to exit the bloodstream, not only to fight infections but also to be involved in multiple inflammatory diseases. Controlling &#946;2 integrin activation presents a viable approach for treating neutrophil-associated inflammatory diseases. In this protocol, a monoclonal antibody, mAb24, which specifically binds to the high-affinity headpiece of &#946;2 integrins, is utilized to quantify &#946;2 integrin activation on isolated primary human neutrophils. N-formylmethionyl-leucyl-phenylalanine (fMLP) is used as a stimulus to activate neutrophil &#946;2 integrins. A high-throughput flow cytometer capable of automatically running 384-well plate samples was used in this study. The effects of 320 chemicals on &#946;2 integrin inhibition are assessed within 3 h. Molecules that directly target &#946;2 integrins or target molecules in the G protein-coupled receptor-initiated integrin inside-out activation signaling pathway can be identified through this approach.

This protocol describes a flow cytometry-based, high-throughput screening method to identify small-molecule drugs that inhibit &#946;2 integrin activation on human neutrophils.